The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and also inflammatory factors are going down and there is a whole NF kappa-b action of metformin that might be part of the our OS and part could be independent even without mitochondria okay it's that confusing but this is the point I want to make I don't know which one of those is important for aging but parts of what you're measuring is the following you fix the aging on a cellular level
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
I think at the end the lower insulin levels the low inflammatory are not necessarily a direct effect and that's why we're we're fighting all the time about what metformin is doing because you measure lots of things but the things you're measuring her because aging was fixed and once aging is fixed then there's a whole ham or dynamic readjustment or whatever you want to call it and then you're measuring that everything and this is not only typical to metformin this is with rapamycin with resveratrol